Identification of Molecular Mechanisms of Coronary Instability in Homogeneous Subsets of Patients With Acute Coronary Syndromes for the Implementation of Precision Medicine

Acute Coronary Syndrome Clinical Trial

— PRECISION  

Official title:

Identification of Molecular Mechanisms of Coronary Instability in Homogeneous Subsets of Patients With Acute Coronary Syndromes for the Implementation of Precision Medicine (PRECISION Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05727982
• Other study ID #: 2747
• Status: Recruiting
• Start date: September 13, 2019
• Est. completion date: September 13, 2024

Study information

• Verified date: February 2023
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Contact: Giovanna GL Liuzzo
• Phone: 06/30154187
• Email: giovanna.liuzzo[@]policlinicogemelli.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To further improve the outcome of ACS it is strongly needed to identify new therapeutic targets. This is possible only by improving our knowledge of the multiple molecular mechanisms leading to coronary instability through several pathways. The goal of this project is to define the molecular mechanisms responsible for the four different presentations of ACS, to identify biomarkers for their noninvasive identification and potential new therapeutic targets, thus promoting precision medicine.

Description:

This is a multicenter prospective observational study, involving 5 Research Units (RU), the enrollment-phase will take 18 months (month 6 to 24). This is an explorative project that will prospectively enroll: 1) Consecutive patients with an admission diagnosis of ACS with Non ST elevation myocardial infarction (NSTEMI) confirmed at coronary angiography, undergoing OCT evaluation of the culprit coronary plaque before stent implantation for clinical reasons and with a clearly identifiable feature of the culprit plaques according to current European guidelines. ECG changes may include transient ST- segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves or pseudo- normalization of T waves or the ECG may be normal. Taking into account our previous studies, the investigators estimated that between 30-35% of NSTEMI patients will undergo OCT evaluation; 2) Consecutive patients with symptoms of Stable Angina (SA) lasting >12 months, angiographically confirmed coronary artery disease, without any episode suggestive of previous acute event, and no overt ischemic episodes during the last 48 hours, according to current European guidelines. Myocardial ischemia was documented by afunctional test (ie, exercise treadmill testing and/or myocardial perfusion imaging). Patients showing Q waves on 12-lead electrocardiogram and/or abnormal echocardiogram (ie, left ventricular ejection fraction <40% and/or wall motion abnormalities) were excluded. NSTEMI (within 12 hours of symptom onset) and SA patients will be enrolled at the time of their admission to the Coronary Care Unit and to the SubIntensive Cardiac Care Unit, of wich Prof. Giovanna Liuzzo (project PI) is the supervising physician; 3) In the same period, consecutive Mitral Valve Disease patients (MVD) with angiographically normal coronary arteries undergoing surgery for mitral valve regurgitation, age and sex matched 1:3 with NSTEMI patients, will be enrolled as control group. MVD patients will be enrolled at Cardiosurgery Operative Unit, lead by Professor Massimo Massetti. Our RU1 will enroll: 1. 150 consecutive patients with an admission diagnosis of NSTEMI. 2. 50 consecutive patients with a diagnosis of SA. 3. 50 consecutive MVD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: September 13, 2024
• Est. primary completion date: September 5, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men and post-menopause women of age 45-80 years; ability to understand and sign the informed consent;
• For NSTEMI and SA patients inclusion criteria will include evidence of obstructive atherosclerosis (> 70% stenosis) at invasive coronary angiography;

Exclusion Criteria:

• Evidence of inflammatory or infectious diseases, malignancies, immunological or haematological disorders;
• Ejection fraction less than 40%;
• Treatment with anti-inflammatory drugs other than low-dose aspirin, and with antibiotic therapies until 1 month before the enrollment.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Chronic Coronary Syndrome
• Syndrome

Intervention

Diagnostic Test:
• Venous blood samples, Biological samples analysis, Cardiology visit.
These interventions are important to study all patients recruited

Locations

Country	Name	City	State
Italy	Fondazione Policlinico Gemelli	Roma
Italy	Fondazione Policlinico Gemelli	Roma

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify homogeneous subsets of ACS patients at OCT interrogation of the culprit plaque	Using Optical Coherence Tomography	2 week
Secondary	Assess the role of shear stress in coronary instability	On OCT-based reconstruction of coronary lesions and fluid dynamics studies;	1 year
Secondary	Establish the most efficient and cost-effective biomarker panel	Establish the most efficient and cost-effective biomarker panel for the identification of homogeneous ACS patient subsets, this approach is relevant especially in centers where OCT is not available and unravel specific mechanisms and players of coronary instability and to identify molecular therapeutic targets, taking advantage of newomics technologies.	1 years